Related Experiment Video

Updated: Jul 9, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Atherosclerosis in patients with biopsy-proven giant cell arteritis

Carlos Gonzalez-Juanatey1, Maria J Lopez-Diaz, Javier Martin

  • 1Hospital Xeral-Calde, Lugo, Spain.

Arthritis and Rheumatism
|December 1, 2007
PubMed

Insights

Giant cell arteritis (GCA) patients showed reduced carotid intima-media thickness compared to controls. Atherosclerosis was not found to be increased in GCA patients, regardless of steroid therapy duration or inflammation markers.

Area of Science:

  • Rheumatology
  • Vascular Medicine
  • Internal Medicine

Background:

  • Giant cell arteritis (GCA) is a systemic vasculitis primarily affecting large and medium-sized arteries.
  • The potential association between GCA and atherosclerosis, a condition characterized by the buildup of plaques in arteries, requires further investigation.

Purpose of the Study:

  • To investigate the prevalence of atherosclerosis in patients with biopsy-proven giant cell arteritis (GCA).
  • To determine if clinical factors, including steroid therapy duration, are associated with atherosclerotic disease development in GCA patients.

Main Methods:

  • A case-control study involving 40 GCA patients and 40 matched controls was conducted.
  • Carotid intima-media thickness (IMT) and carotid plaques were assessed using high-resolution B-mode ultrasound.

Main Results:

  • GCA patients exhibited significantly lower carotid artery IMT compared to matched controls (P = 0.005).
  • No statistically significant correlation was found between carotid IMT and disease duration, inflammation markers, or cumulative prednisone dose after adjusting for covariates.
  • A positive correlation was observed between age and carotid IMT in GCA patients (r = 0.673, P < 0.001).

Conclusions:

  • Atherosclerotic macrovascular disease is not elevated in patients diagnosed with giant cell arteritis.
  • The findings suggest that GCA itself may not confer an increased risk for atherosclerosis.
Abstract

More Related Videos

Mouse Models for Graft Arteriosclerosis07:37

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...